中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China

文献类型：期刊论文

作者Zhang, Xiangyu1; Zeng, Liang1; Li, Yizhi1; Xu, Qinqin2; Yang, Haiyan1; Lizaso, Analyn3; Mao, Xinru3; Jin, Ren'an4; Zeng, Yu5; Li, Qinglin6
刊名CANCER IMMUNOLOGY IMMUNOTHERAPY
出版日期2021-02-10
ISSN号0340-7004
关键词Anlotinib Immunotherapy Programmed death 1 inhibitor Lung cancer
DOI10.1007/s00262-021-02869-9
通讯作者Zhang, Yongchang(zhangyongchang@csu.edu.cn) ; Yang, Nong(yangnong0217@163.cn)
英文摘要Background This study evaluated the efficacy and safety of anlotinib combined with programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Patients and methods SCLC (n = 28) and NSCLC (n = 177) patients who received treatment at Hunan Cancer Hospital between June 1, 2019, and July 1, 2020, were retrospectively analyzed. Progression-free survival (PFS) and treatment responses were compared among patients who received combination therapy of anlotinib plus PD-1 inhibitor, or monotherapy of either chemotherapy or PD-1 inhibitor. Independent prognostic factors were identified by Cox regression analysis. Results Patients with relapsed SCLC who received anlotinib plus PD-1 inhibitor as a >= second-line therapy (n = 14) had a significantly longer PFS than those who received PD-1 inhibitor alone (n = 14, 5.0 vs. 3.0 months; P = 0.005). For patients with previously untreated wild-type NSCLC, the combination therapy in the first-line setting (n = 6) provided a marginally longer PFS than mono-chemotherapy (n = 6, 8.0 vs. 3.0 months; P = 0.075). For patients with relapsed NSCLC, the combination therapy in the >= second-line setting (n = 62) resulted in significantly higher objective response rate (19.3 vs. 5.0 vs. 2.4%; P = 0.013) and longer PFS (8.0 vs. 2.0 vs. 2.0 months; P <0.001) as compared to monotherapy of either chemotherapy (n = 41) or PD-1 inhibitor (n = 62). Anlotinib and PD-1 blockade combination therapy was an independent predictive factor of longer PFS (P <0.001). Conclusion The combination of anlotinib and PD-1 inhibitor has promising efficacy and manageable toxicity as a second- or later-line treatment of relapsed NSCLC and possibly for relapsed SCLC.
资助项目Natural Science Foundation of China[81760529] ; Natural Science Foundation of Hunan Province[2018RS3106] ; Natural Science Foundation of Hunan Province[2018SK50901] ; Natural Science Foundation of Hunan Province[kq1801102] ; Natural Science Foundation of Hunan Province[2019-TJ-N04] ; Natural Science Foundation of Hunan Province[2019JJ50357] ; Natural Science Foundation of Hunan Province[2019SK4010] ; Natural Science Foundation of Hunan Province[2020JJ5340] ; Natural Science Foundation of Hunan Province[2020JJ3025]
WOS研究方向Oncology ; Immunology
语种英语
出版者SPRINGER
WOS记录号WOS:000616738100001
资助机构Natural Science Foundation of China ; Natural Science Foundation of Hunan Province
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/119644]  
专题中国科学院合肥物质科学研究院
通讯作者Zhang, Yongchang; Yang, Nong
作者单位1.Cent South Univ, Hunan Canc Hosp, Dept Med Oncol,Xiangya Sch Med, Lung Canc & Gastrointestinal Unit,Affiliated Canc, Changsha 410013, Peoples R China
2.Qinghai Prov Peoples Hosp, Xining 810000, Peoples R China
3.Burning Rock Biotech, Guangzhou 510300, Peoples R China
4.Zhejiang Univ, Sir Run Run Shaw Hosp, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China
5.Tongji Univ, Tongji Hosp, Dept Pathol, Sch Med, Shanghai, Peoples R China
6.Univ Chinese Acad Sci, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China
7.Shandong Univ, Dept Radiotherapy, Qilu Hosp, Jinan, Shandong, Peoples R China
8.Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei, Peoples R China
9.Univ South China, Grad Sch, Hengyang 421001, Hunan, Peoples R China
推荐引用方式
GB/T 7714		 Zhang, Xiangyu,Zeng, Liang,Li, Yizhi,et al. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY,2021.
APA Zhang, Xiangyu.,Zeng, Liang.,Li, Yizhi.,Xu, Qinqin.,Yang, Haiyan.,...&Yang, Nong.(2021).Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.CANCER IMMUNOLOGY IMMUNOTHERAPY.
MLA Zhang, Xiangyu,et al."Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China".CANCER IMMUNOLOGY IMMUNOTHERAPY (2021).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。